<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905291</url>
  </required_header>
  <id_info>
    <org_study_id>MT11-KR17SMF115</org_study_id>
    <nct_id>NCT03905291</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Single Center, Dose Escalation, Phase I Study to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the pharmacokinetic/pharmacodynamic characteristics and safety/tolerability of
      MT921 in Healthy Subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Actual">December 26, 2018</completion_date>
  <primary_completion_date type="Actual">December 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) measured by Liquid Chromatography-mass spectrometry (LC/MS)</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Peak plasma concentration measured by Liquid Chromatography-mass spectrometry (LC/MS) achieving in the test area of the body after administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to 24 hours measured by Liquid Chromatography-mass spectrometry (LC/MS) after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Time (Tmax) measured by Liquid Chromatography-mass spectrometry (LC/MS)</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>The time at which the Cmax is observed measured by Liquid Chromatography-mass spectrometry (LC/MS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2) measured by Liquid Chromatography-mass spectrometry (LC/MS)</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>The time it takes for the concentration of the drug in the plasma or the total amount in the body to be reduced by 50% measured by Liquid Chromatography-mass spectrometry (LC/MS).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events as assessed by MedDRA version 17.0</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Assessment of safety in investigational product with the number of participants with adverse events as assessed by MedDRA version 17.0.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT921 60 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT921 120 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT921 160 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 60 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 120 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 150 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT921</intervention_name>
    <description>Formulated as an injectable solution</description>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_label>Treatment Group 2</arm_group_label>
    <arm_group_label>Treatment Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normal saline</description>
    <arm_group_label>Treatment Group 4</arm_group_label>
    <arm_group_label>Treatment Group 5</arm_group_label>
    <arm_group_label>Treatment Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged between 20 and 65 years

        Exclusion Criteria:

          -  Subject not appropriate for participating in this study according to the
             investigator's opinion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

